

# **11th Annual PEGS Europe 2019**

Abstracts

Lisbon, Portugal  
18 – 22 November 2019

ISBN: 978-1-7138-0961-6

**Printed from e-media with permission by:**

Curran Associates, Inc.  
57 Morehouse Lane  
Red Hook, NY 12571



**Some format issues inherent in the e-media version may also appear in this print version.**

Copyright© (2019) by Cambridge EnerTech  
All rights reserved.

Printed with permission by Curran Associates, Inc. (2020)

For permission requests, please contact Cambridge EnerTech  
at the address below.

Cambridge EnerTech  
Cambridge Innovation institute  
250 First Avenue  
Suite 300  
Needham, MA 02494  
USA

Phone: 781-972-5400  
Fax: 781-972-5425

[ce@cambridgeenertech.com](mailto:ce@cambridgeenertech.com)

**Additional copies of this publication are available from:**

Curran Associates, Inc.  
57 Morehouse Lane  
Red Hook, NY 12571 USA  
Phone: 845-758-0400  
Fax: 845-758-2633  
Email: [curran@proceedings.com](mailto:curran@proceedings.com)  
Web: [www.proceedings.com](http://www.proceedings.com)

# TABLE OF CONTENTS

POTENTIAL OF AGGREGATED ANTIGENS FOR STRONG IMMUNITY.....	1
<i>M. Akutsu</i>	
ENZYMATIC CROSSLINKING OF SMALL ANTIBODY AND CATIONIC PEPTIDE FOR SIRNA DELIVERY .....	2
<i>Y. Ando</i>	
ANTI-HUMAN CXCR4 AND ANTI-HUMAN IL-7R ANTIBODIES SELECTED FROM NON- IMMUNE REPERTOIRES .....	3
<i>J. Assuncao</i>	
PRESTIGE ANTIBODIES: ANTIBODIES COVERING THE HUMAN PROTEOME AND TRUST THROUGH CHARACTERIZATION.....	4
<i>A. Bergkvist</i>	
RECOMBINANT HUMAN ANTIBODIES AGAINST STAPHYLOCOCCUS AUREUS SURFACE PROTEINS .....	5
<i>F. Bertoglio</i>	
CHARACTERISATION OF OFF TARGET PEPTIDE REPERTOIRES FOR T CELL RECEPTORS THAT TARGET THE CANCER TESTIS ANTIGEN NY-ESO-1[157-165]-HLA- A*02:01 .....	7
<i>I. Bombik</i>	
THERAPEUTIC ANTIBODIES FOR VETERINARY MEDICINE .....	8
<i>V. Brand</i>	
GENERATION OF A UNIQUE ANTIBODY TARGETING THE ONCOGENIC C11ORF95- RELA FUSION AS A TRANSFORMATIVE DIAGNOSTIC FOR SUPRATENTORIAL EPENDYMOMA .....	10
<i>D. Chan</i>	
CARDIS: NEXT GENERATION CAR DISCOVERY .....	11
<i>E. Chantzoura</i>	
DISCOVERY OF NOVEL PROSTATE CANCER TARGETED PEPTIDES AND THEIR USE IN DRUG DELIVERY .....	12
<i>A. Cohen</i>	
DISCOVERY OF ANTIBODIES FOR IMMUNOTHERAPY OF CRC USING PHAGE DISPLAY .....	13
<i>S. Deshmukh</i>	
DEVELOPMENT OF A NEW HUMAN CELL-FREE SYSTEM FOR PROTEIN SYNTHESIS .....	14
<i>R. Santos</i>	
COFACTOR PROMISCUITY OF MAMMALIAN SENESCENCE MARKER PROTEIN (SMP30) .....	15
<i>R. Dutta</i>	
REAL-TIME CELL-BASED ASSAYS WITH LIGANDTRACER TECHNOLOGY: CHARACTERIZING MOLECULAR INTERACTIONS ON LIVING SUSPENSION CELLS.....	16
<i>J. Encarnacao</i>	

A NEW ENTERPRISE SOFTWARE PLATFORM FOR EFFICIENT LARGE-SCALE ANTIBODY CHARACTERIZATION AND EPITOPE BINNING.....	17
<i>L. Florez</i>	
KEEPING KINETICS REAL .....	18
<i>J. Galindo</i>	
A NEW SMALL-MOLECULE-DRUG-CONJUGATE PLATFORM FOR TARGETED TUMOR THERAPY: ALPHA-AMANITIN-BASED DRUG CONJUGATES TARGETING PSMA .....	19
<i>F. Gallo</i>	
NOVEL IL17 HUMANIZED MOUSE MODELS FOR PRECLINICAL PHARMACOLOGY STUDY OF THERAPEUTICS AGAINST IL17 .....	21
<i>T. Gan</i>	
TURNING A NEGATIVE TO A POSITIVE WITH ANTI-METATYPE AFFIMER® REAGENTS .....	22
<i>D. Gare</i>	
SYNTHETIC DNA TECHNOLOGIES ENABLE SINGLE DOMAIN ANTIBODY DISCOVERY.....	23
<i>P. Garg</i>	
DEEP SEQUENCING NGS ANALYSIS OF PHAGE SELECTION OUTPUTS PRODUCE CONSENSUS MOTIFS VALIDATED BY CRYSTAL STRUCTURE DETERMINATION.....	24
<i>A. Goncalves</i>	
FROM MACROCYCLIC PEPTIDES TO NANOBODIES: TARGETING ANGIOPOIETIN-LIKE PROTEIN 4 USING DISPLAY TECHNOLOGIES .....	25
<i>A. Gutgsell</i>	
CHICKEN SCFV MOLECULES FOR DOWNSTREAM PROCESSING OF SOPHISTICATED ANTIGENS .....	27
<i>S. Hinz</i>	
DEVELOPING NEW ANTIBODIES TO TARGET TREG CELLS USING THE PATIENT CENTRIC F.I.R.S.T.TM PLATFORM.....	28
<i>P. Holmkvist</i>	
A PROLINE AND ALANINE-SPECIFIC PROTEASE FOR PROTEIN CHARACTERIZATION BY MASS SPECTROMETRY .....	29
<i>C. Hosfield</i>	
DISCOVERY OF FUNCTIONAL MONOCLONAL ANTIBODIES AGAINST KV1.3 AND KCA3.1 USING THE TETRAEXPRESS PROTEIN EXPRESSION PLATFORM.....	30
<i>S. Hussain</i>	
THE BEST OF BOTH WORLDS: BULK REPERTOIRE SEQUENCING WITH SINGLE CELL FUNCTION.....	31
<i>Y. Hwang</i>	
DRUG DISCOVERY USING RECYCLING AND SWEEPING ANTIBODY TECHNOLOGY.....	32
<i>T. Igawa</i>	
DISCOVERY AND APPLICATION OF PEPTIDES SPECIFIC FOR ACUTE MYELOGENOUS LEUKEMIC CELLS .....	33
<i>Y. Katzman</i>	

HUMANIZED NSG-TG(HU-IL15) MICE ENHANCE THE DEVELOPMENT OF HUMAN NK CELLS AND SUPPORT PRECLINICAL IMMUNE-ONCOLOGY EFFICACY FOR TESTING OF NK CELL BASED IMMUNOTHERAPY .....	34
<i>J. Keck</i>	
MICROFLUIDIC MODULATION SPECTROSCOPY (MMS) – A NEW APPROACH TO OBTAINING DATA RICH IR SPECTRA FOR PROTEIN SECONDARY STRUCTURE ELUCIDATION .....	35
<i>P. King</i>	
A PLATFORM APPROACH TO MANAGE DEVELOPABILITY AND MANUFACTURABILITY RISKS OF BIOLOGICS MOLECULES .....	36
<i>S. Kolinko</i>	
LOOP GRAFTING AS A NOVEL METHOD TO DESIGN STABLE FC-SILENT ANTIBODIES.....	37
<i>J. Konc</i>	
BRIDGING MOA-BASED ADCC REPORTER BIOASSAY WITH AN IMPROVED PBMC-BASED ADCC CYTOTOXICITY ASSAY FOR IMMUNOTHERAPY MONOCLONAL ANTIBODY DEVELOPMENT.....	38
<i>G. Krishnan</i>	
KUHNER FEEDING TECHNOLOGY .....	39
<i>M. Landenberger</i>	
ANTI-PD-L1 FC FUSION AFFIMER BIOTHERAPEUTICS: CELL LINE AND PROCESS DEVELOPMENT .....	41
<i>F. Laurent</i>	
FACILITATING THE CAPTURE AND INTEGRATION OF CONSISTENTLY STRUCTURED EXPERIMENTAL DATA .....	42
<i>J. Leadley</i>	
CHALLENGING THE BIOPHARMACEUTICALS PROCESSING STATUS QUO: A QBD BENCHMARK OF SPRAY-DRYING AND LAMINARPACE VERSUS CLASSIC FREEZE-DRYING .....	43
<i>P. Lino</i>	
A SYNTHETIC HUMAN HYPERIMMUNE ANTIBODY LIBRARY FOR DRUG DISCOVERY.....	45
<i>Q. Liu</i>	
KOZANE: A PRIMER GENERATOR FOR SITE-DIRECTED MUTAGENESIS.....	46
<i>M. Lundqvist</i>	
DEVELOPMENT AND ULTRAFAST LASER STUDIES OF PHOTOACTIVE PROTEIN BIOCONJUGATES .....	47
<i>R. Malde</i>	
FROM SITE-SELECTIVE BIOCONJUGATION OF CYSTEINES OR TRYPTOPHANS TO GENERAL TARGETING OF AROMATIC RESIDUES: NOVEL CHEMISTRY FOR BIOCONJUGATION, STRUCTURAL PROTEOMICS AND INTERACTOMICS .....	48
<i>V. Matousek</i>	
SYNTHESIS AND FUNCTIONAL CHARACTERIZATION OF SNAKE TOXINS USING CELL-FREE EXPRESSION .....	50
<i>M. Menezes</i>	

EMPLOYING THE MS-BASED MULTI-ATTRIBUTE METHOD (MAM) FOR AUTOMATED QUALITY MONITORING OF BIOTHERAPEUTICS .....	51
<i>J. Mercier</i>	
GENERATING HIGH AFFINITY COMMON LIGHT FABs AS A FOUNDATION TO BEAT™ 2.0.....	52
<i>T. Monney</i>	
A RATIONAL AFFINITY MATURATION PLATFORM.....	53
<i>H. Morgan</i>	
WHICH ANTIBODY SOURCE LEADS TO SUCCESS? A COMPARISON STUDY BETWEEN IMMUNE, SYNTHETIC, AND NAIVE LIBRARIES FOR PHAGE DISPLAY ANTIBODY DISCOVERY .....	54
<i>N. Mouz</i>	
INCREASED TUMOR PENETRATION OF SINGLE-DOMAIN ANTIBODY DRUG CONJUGATES IMPROVES IN VIVO EFFICACY IN PROSTATE CANCER MODELS .....	55
<i>I. Nessler</i>	
CODONADJUST: A SOFTWARE FOR IN SILICO DESIGN OF A MUTAGENESIS LIBRARY WITH SPECIFIC AMINO ACID PROFILES .....	56
<i>T. Nguyen</i>	
FROM DISCOVERY TO LICENSE - LONZA'S EXPERIENCE OF COMPLEX PROTEINS .....	57
<i>C. Nobrega</i>	
VALUE PROPOSITION OF INTEGRATED ADC MANUFACTURING PROCESSES – USE OF ECONOMIC MODELLING .....	58
<i>R. Noel</i>	
EARLY IMMUNOGENICITY RISK ASSESSMENT: A SUITE OF ASSAYS TO GUIDE LEAD CANDIDATE SELECTION .....	59
<i>S. Pattijn</i>	
DEVELOPMENT OF AN ADVANCED CHO CELL EXPRESSION SYSTEM FOR INCREASED TRANSIENT PROTEIN PRODUCTION .....	60
<i>C. Peigne</i>	
THE JOURNEY TO "THE" ANTIBODY: ACCESSING A VERSATILE TOOLBOX.....	61
<i>C. Pereira</i>	
COMBINATION OF RIBOSOME DISPLAY AND NEXT GENERATION SEQUENCING AS A POWERFUL METHOD FOR IDENTIFICATION OF AFFIBODY BINDERS AGAINST $\hat{A}$ - LACTAMASE CTX-M15.....	62
<i>S. Potisopon</i>	
A NOVEL METHOD FOR SCREENING LARGE ANTIBODY LIBRARIES AGAINST MEMBRANE PROTEIN TARGETS IN MAMMALIAN CELLS .....	63
<i>N. Robertson</i>	
DISPLAYING BIOLOGICALLY ACTIVE INTERLEUKIN-2 ON FILAMENTOUS PHAGES: FROM EPITOPE MAPPING TO DIRECTED EVOLUTION OF NOVEL PHAGEKINES.....	65
<i>G. Rojas</i>	

LIPOPARTICLES ADVANCE ANTIBODY DISCOVERY AGAINST CHALLENGING MULTIPASS MEMBRANE PROTEIN TARGETS .....	66
<i>J. Rucker</i>	
GLYCOENGINEERED MURINE ANTIBODIES AS SURROGATES TO THE HUMANIZED AND ADCC-ENHANCED ANTI-IL1RAP ANTIBODY CAN04 (NIDANILIMAB) .....	67
<i>C. Millrud</i>	
PRODUCTION OF LYSOZYME-PLGA LOADED MICROPARTICLES FOR CONTROLLED RELEASE BY HOT MELT EXTRUSION TECHNOLOGY USING DESIGN-OF- EXPERIMENTS TOOL .....	69
<i>J. Sa</i>	
INVESTIGATION OF METABOLIC AND PHYSIOLOGICAL CHANGES ASSOCIATED WITH INCREASED ERYTHROPOIETIN PRODUCTION AND SECRETION BY HEK293 CELLS .....	71
<i>R. Saghaleyni</i>	
HOMOGENEOUS, SERUM STABLE ADCS USING NEXT GENERATION MALEIMIDE AND PYRIDAZINEDIONE LINKERS .....	73
<i>L. Salerno</i>	
IN VITRO EXPRESSION OF SINGLE-CHAIN VARIABLE FRAGMENTS AND THEIR COMPARISON WITH IN VIVO E. COLI PRODUCTION .....	74
<i>J. Sampaio</i>	
EXPEDITING DEVELOPMENT OF BIOLOGICS USING PRECISELY DEFINED SYNTHETIC DNA MUTANT LIBRARIES .....	75
<i>M. Sandros</i>	
HIGH-THROUGHPUT AND COMPREHENSIVE CHARACTERIZATION OF FORCED DEGRADATION OF ANTIBODY DRUG CONJUGATES (ADCS) BY LC-MS AND -MS/MS .....	76
<i>A. Schummer</i>	
EVALUATION OF IMMUNOINFORMATIC TOOLS FOR ANALYSIS OF ANTIBODY REPertoire SEQUENCES .....	78
<i>E. Smakaj</i>	
TRANSLATING ANTIBODY FRAGMENT DRUG-CONJUGATES (FDCS) FROM CONCEPT TO CLINIC .....	80
<i>B. Stenton</i>	
FULL IN VITRO SELECTION OF SYNTHETIC HUMANIZED NANOBODIES FOR BASIC AND CANCER RESEARCH .....	81
<i>C. Sybillin</i>	
THE SPECIFICA GENERATION 3 ANTIBODY LIBRARY PLATFORM: DRUG-LIKE ANTIBODIES STRAIGHT FROM SELECTIONS .....	82
<i>A. Teixeira</i>	
PREDICTING PROTEIN-PROTEIN BINDING SITES AND EPITOPE MAPPING .....	83
<i>N. Thorsteinson</i>	
SITE-SPECIFIC GLYCLICK® ANTIBODY CONJUGATES SUITABLE FOR RADIOIMMUNO-AND FLUROESCENT IMAGING .....	84
<i>H. Toftevall</i>	

APPLICATION OF NEXT GENERATION PHAGE DISPLAY COUPLED WITH PHAGE MICROARRAY TO DEVELOP EARLY DIAGNOSTICS FOR RENAL CELL CARCINOMA.....	85
<i>M. Tsoumpeli</i>	
MACHINE-LEARNING APPLICATION FOR DIRECTED EVOLUTION OF FUNCTIONAL PROTEINS.....	86
<i>M. Umetsu</i>	
TRICYCLIC PEPTIDES VIA TEMPLATED TANDEM CLIPS/CUAAC CYCLIZATIONS.....	87
<i>J. Heteren</i>	
EXPLORING JAPANESE QUAIL IMMUNE REPERTOIRES FOR ANTIBODY DISCOVERY.....	88
<i>R. Vieria-Pires</i>	
DEEP LEARNING ENABLES THERAPEUTIC ANTIBODY OPTIMIZATION IN MAMMALIAN CELLS.....	89
<i>B. Wagner</i>	
PROGNOSTIC AND POTENTIAL PREDICTIVE SIGNIFICANCE OF AN INTEGRATED MORPHOLOGIC, IMMUNOPHENOTYPIC AND GENOMIC CLASSIFICATION OF PANCREATIC DUCTAL ADENOCARCINOMA.....	90
<i>M. Wartenberg</i>	
INTERLEUKIN-10-FC FUSION PROTEINS STIMULATE ANTITUMOR IMMUNITY IN A PRECLINICAL MODEL OF COLORECTAL CANCER.....	92
<i>M. Whitmore</i>	
SPECIFICITY PROFILING AND EPITOPE MAPPING OF MONOCLONAL ANTIBODIES TARGETING MEMBRANE PROTEINS.....	93
<i>S. Willis</i>	
COMBINATION OF DEEP LEARNING AND IN VITRO ANALYSES FOR IMMUNOGENICITY ASSESSMENT OF BIOTHERAPEUTICS.....	94
<i>J. Woo</i>	
FUNCTIONAL EVALUATION OF UNIQUE ANTI-PDL1 ANTIBODIES GENERATED THROUGH SINGLE PLASMA B CELL CLONING ON THE BEACON® PLATFORM VERSUS A STANDARD HYBRIDOMA APPROACH.....	95
<i>T. Yang</i>	
GENERATION OF ANTAGONIST GPCR ANTIBODY (APELIN RECEPTOR) WITH NOVEL DENDRITIC CELL BASED IMMUNIZATION STRATEGY.....	97
<i>T. Yang</i>	
DEVELOPMENT AND APPLICATION OF ICOS/ICOSL PATHWAY IMMUNE ACTIVATOR PROTEIN DRUG.....	98
<i>C. Yu</i>	
TRI-MANNOSE ANTIBODY: A NOVEL SITE-SPECIFIC AND DUAL PAYLOAD GLYCOENGINEERING ANTIBODY DRUG CONJUGATION PLATFORM.....	99
<i>S. Yu</i>	
TAO: TWIST ANTIBODY OPTIMIZATION OF AN ANTI-PD-1 ANTIBODY.....	100
<i>T. Yuan</i>	



NOVEL SULFUR LINKED DIHYDROARTEMISININ INHIBITS GROWTH AND MIGRATION OF PC-3 CELLS BY DOWN REGULATING PIN-1 .....	101
<i>F. Ahmad</i>	
TAPPING INTO NATURE TO OVERCOME LIMITS IN ANTIBODY DISCOVERY AGAINST MEMBRANE PROTEINS .....	102
<i>F. Ahmed</i>	
INCREASED HCP IDENTIFICATION CAPABILITIES WITH A PASEF ENABLED ULTRA- HIGH RESOLUTION QTOF.....	104
<i>C. Albers</i>	
ENGINEERED MONOALLELIC HLA AND TUMOR-ASSOCIATED ANTIGEN EXPRESSION CELL LINES FOR IMMUNO-ONCOLOGY RESEARCH.....	105
<i>M. Althage</i>	
INDIVIDUAL HCPS IDENTIFICATION AND QUANTIFICATION IN THE DOWNSTREAM PROCESS OF OMOMYC CELL PENETRATING PEPTIDE BY LC-MS/MS.....	106
<i>M. Beaulieu</i>	
IMPROVING CONFIDENCE AND PRODUCTIVITY FOR N-LINKED GLYCAN ANALYSIS IN BIOTHERAPEUTICS DEVELOPMENT USING AN INTEGRATED AND COMPACT LC- FLR-HRMS SYSTEM .....	107
<i>G. Bechade</i>	
FORMATION AND CLEARANCE OF TNF-DRUG COMPLEXES DURING TNF INHIBITOR TREATMENT.....	109
<i>L. Berkhout</i>	
HERA-CD27L, A TRUE CD27 AGONIST, IS A HEXAVALENT SCCD27L-FC FUSION PROTEIN ENHANCING T CELL ACTIVATION FOR POTENT ANTI-TUMOR IMMUNITY .....	111
<i>K. Billian-Frey</i>	
THE POWER OF IN VITRO ASSAYS IN IMMUNO-ONCOLOGY DRUG DEVELOPMENT .....	112
<i>E. Boelen</i>	
A GENERAL APPROACH FOR THE DEVELOPMENT OF COMMON LIGHT CHAIN BASED BISPECIFICS WITH PH RESPONSIVE BINDING MODALITIES .....	113
<i>J. Bogen</i>	
NOVEL SOLUTION FOR HTP ANTIBODY PURIFICATION USING MAGNETIC BEAD BASED SYSTEM.....	114
<i>R. Bogoev</i>	
AUTOMATED MAB WORKFLOWS: COMBINING MULTIDIMENSIONAL (MULTI-D) PURIFICATIONS WITH PRODUCT ANALYSIS.....	115
<i>K. Boutaga</i>	
ALICE® - MAKES PRODUCTION OF DIFFICULT-TO-EXPRESS PROTEINS EASY .....	116
<i>S. Brosch</i>	
NANOBODIES AS HIGHLY SPECIFIC, RECOMBINANT SECONDARY ANTIBODIES.....	117
<i>A. Buchfellner</i>	
MEASURING T-CELL AVIDITY USING ACOUSTIC FORCE-BASED TECHNOLOGY IN A LABEL-FREE MANNER.....	118
<i>A. Candelli</i>	

PROTEIN-BASED SELECTIVE NANOCONJUGATE AGAINST METASTATIC STEM CELLS OF HUMAN COLORECTAL CANCER .....	119
<i>O. Cano-Garrido</i>	
ONE-STEP MODIFICATION OF MPEGYLATED NANOPARTICLES BY HUMANIZED BISPECIFIC ANTIBODIES FOR SELECTIVE THERAPY .....	121
<i>T. Cheng</i>	
A NOVEL SCALE-DOWN TECHNIQUE TO RAPIDLY CHARACTERIZE PROTEIN AGGREGATION POTENTIAL .....	122
<i>V. Chhabria</i>	
XTENCHO™: HIGH PERFORMANCE CHO CELLS DEVELOPED FOR TRANSIENT EXPRESSION OF THERAPEUTIC PROTEINS.....	123
<i>C. Chicois</i>	
THERAPEUTIC TARGETING OF ONCOFETAL CSA ON VARIOUS CANCERS USING RVAR2-VC-MMAE .....	124
<i>S. Choudhary</i>	
A NOVEL BACTERIAL $\beta$ -GLUCURONIDASE INHIBITORS TCH-3511 AS ORAL ADJUVANT TO ALLEVIATE CANCER DRUG TOXICITY AND TO BE FAP DRUG CANDIDATES .....	125
<i>C. Chuang</i>	
A NEW MULTI-ATTRIBUTE METHOD: ION EXCHANGE CHROMATOGRAPHY OF BIOPHARMACEUTICAL PROTEINS COUPLED DIRECTLY TO HIGH RESOLUTION MASS SPECTROMETRY .....	127
<i>K. Cook</i>	
A MUCIN 16 BISPECIFIC T CELL-ENGAGING ANTIBODY FOR THE TREATMENT OF OVARIAN CANCER .....	128
<i>A. Crawford</i>	
DESIGN OF A FAST STRUCTURAL STABILITY PROFILE WORKFLOW TO CHARACTERIZE BIOPHARMACEUTICALS .....	129
<i>J. Cristovao</i>	
IDENTIFICATION AND VALIDATION OF BREAST CANCER NEOANTIGENS USING IN SILICO METHODOLOGIES .....	131
<i>P. Neves</i>	
BIOPHYSICAL CHARACTERIZATION AND COMPARISON OF RECOMBINANT AND HYBRIDOMA ANTIBODIES.....	133
<i>S. Acosta</i>	
A NOVEL PRECLINICAL MODEL FOR PERINEURAL INVASION OF CUTANEOUS SCCHN TO TEST COMBINATION THERAPIES .....	134
<i>P. Lima</i>	
REMOVING THE AGGREGATES OF AN ACIDIC MONOCLONAL ANTIBODY WITH A MIXED-MODE CHROMATOGRAPHY MEDIA.....	135
<i>J. Depoisier</i>	
ENGINEERING MONO- AND MULTI-VALENT INHIBITORS ON A MODULAR SCAFFOLD.....	136
<i>A. Diamante</i>	

EVALUATION OF AN AUTOMATED, ACIDIC PH PROTEIN DIGESTION FOR REDUCED LEVELS OF ARTIFICIAL DEAMIDATION IN BIOTHERAPEUTIC PEPTIDE MAPPING STUDIES .....	137
<i>K. D'Silva</i>	
DEVELOPMENT OF A FULLY HUMAN ANTIBODY AGAINST A KEY IMMUNE CHECKPOINT MODULATOR .....	138
<i>A. Dudek</i>	
QUANTITATIVE CELL-BASED BIOASSAYS TO ADVANCE IMMUNOTHERAPY PROGRAMS TARGETING IMMUNE CHECKPOINT RECEPTORS .....	139
<i>S. Edenson</i>	
BISPECIFIC ANTIBODY ENGINEERING IN MAMMALIAN CELLS BY MULTI-STEP GENOME EDITING.....	140
<i>R. Ehling</i>	
THERAPEUTIC MONOCLONAL ANTIBODIES OF IGG1 CLASS DECORATE BLOOD IMMUNE CELLS RESULTING IN INSTANT NK CELL ACTIVATION THROUGH FCGR3A .....	141
<i>M. Eltahir</i>	
A GENERIC PLATFORM FOR THE ISOLATION OF HUMANIZED ANTIBODIES BASED ON CHICKEN IMMUNIZATION AND YEAST SURFACE DISPLAY .....	143
<i>A. Elter</i>	
DIRECT CHARACTERIZATION OF LMW IMPURITIES USING MS.....	144
<i>H. Falkenberg</i>	
COMPLETE WORKFLOW SOLUTIONS - A ONE-STOP SHOP FOR EVERYTHING GENE TO PROTEIN COMBINE HIGHLY ADVANCED EXPRESSION SYSTEMS WITH EXPRESSION OPTIMIZED GENES.....	145
<i>S. Fath</i>	
HIGH-THROUGHPUT EXPRESSION AND PURIFICATION PIPELINE AT THE SGC OXFORD .....	146
<i>A. Fernandez-Cid</i>	
MOUSE MODELS FOR IN VIVO EVALUATION OF CAR-T OR BISPECIFIC ANTIBODY THERAPY EFFICACY .....	147
<i>A. Flora</i>	
BIACORE 8K+ DELIVERING HIGH THROUGHPUT METHODS FOR CHARACTERISING MULTIVALENT PROTEINS .....	149
<i>N. Ford</i>	
IMMUNODEFICIENT HUMAN FCRN TRANSGENIC MICE PROVIDE PK WITHOUT ADA.....	150
<i>R. Gareus</i>	
A WORKFLOW-DRIVEN PLATFORM SOLUTION FOR MAM-BASED CRITICAL QUALITY ATTRIBUTE (CQA) MONITORING OF BIOTHERAPEUTICS IN PROCESS DEVELOPMENT AND QC.....	151
<i>H. Gastall</i>	
HT SOLUTION FOR ENDOTOXIN LEVEL MEASUREMENT.....	152
<i>S. Gfell</i>	

MEASUREMENT OF AGGREGATION IN HIGH CONCENTRATION BIOPHARMACEUTICAL FORMULATIONS BY MICROBORE SEC WITH UV IMAGING DETECTION.....	153
<i>D. Goodall</i>	
AUTOMATED LOW VOLUME SUBVISIBLE PARTICLE ANALYSIS WITH THE HORIZON SYSTEM.....	155
<i>R. Gordon</i>	
CD4+ AND CD8+ TCR $\alpha$ -DEFICIENT BIOLUMINESCENT REPORTER T CELLS FOR SCREENING AND CHARACTERIZATION OF NEOANTIGEN-SPECIFIC TCRS.....	156
<i>J. Grailer</i>	
CURRENT STATE AND PERSPECTIVES OF SMALL ANGLE X-RAY SCATTERING FOR PHARMACEUTICAL AND BIOTECHNOLOGICAL COMPANIES .....	157
<i>M. Grawert</i>	
NOVEL, IMPROVED CELL-BASED ASSAYS TO ENABLE IMMUNOTHERAPY DRUG DEVELOPMENT FOR CHECKPOINT RECEPTORS .....	158
<i>A. Green</i>	
TO COMPARE THE SHEAR EFFECT OF LEVITATING PUMP AND PERISTALTIC PUMPS .....	159
<i>M. Gupta</i>	
COMPREHENSIVE FUNCTIONAL PROFILING OF ANTI-ZIKA VIRUS ANTIBODIES FROM CONVALESCENT ZIKA VIRUS DISEASE PATIENTS.....	160
<i>M Gutierrez-Gonzalez</i>	
A NEXT GENERATION BISPECIFIC ANTIBODY PLATFORM FOR EFFECTIVE TUMOR CELL KILLING WITH MINIMAL CYTOKINE RELEASE.....	161
<i>K. Harris</i>	
ITERATION OF LIBRARY DESIGN FROM ANTIBODY DATABASE FOR THERMAL STABILITY .....	162
<i>S. Hattori</i>	
BEYOND REVERSE PHASE: NEW LC/MS METHODS FOR UNCOVERING PROTEIN STRUCTURE.....	163
<i>S. Heidelberger</i>	
CREATING FOCUSED LIBRARIES FOR PROTEIN ENGINEERING .....	164
<i>A. Henry</i>	
INDUSTRIALIZING IMMUNO-ONCOLOGY THERAPEUTIC DISCOVERY PLATFORMS .....	165
<i>J. Hersch</i>	
CUSTOMIZED GLYCOSYLATION OF THERAPEUTICS VIA A NOVEL PRODUCTION PLATFORM.....	166
<i>S. Herwig</i>	
TETRA-SPECIFIC MATCH4 ANTIBODIES MEDIATE CONCOMITANT BLOCKADE OF PD-L1 AND POTENT T CELL-STIMULATION, LOCALLY RESTRICTED TO HER2+ TUMORS .....	167
<i>C. Hess</i>	
THE SALIPRO $\text{\textcircled{R}}$ SYSTEM FOR THERAPEUTIC DISCOVERY TARGETING GPCRS, ION CHANNELS AND TRANSPORTERS.....	168
<i>A. Heuer</i>	

THE NOVEL ANTIBODY LOCK TO ENHANCE ANTIBODY DRUG DISEASE SELECTIVITY AND REDUCE SIDE EFFECTS.....	169
<i>K. Ho</i>	
TCER - DESIGN AND CHARACTERIZATION OF OPTIMAL SCAFFOLDS FOR BISPECIFIC T CELL RECEPTOR THERAPEUTICS.....	170
<i>M. Hofmann</i>	
INTEIN MEDIATED HIGH THROUGHPUT SCREENING FOR BISPECIFIC ANTIBODIES .....	171
<i>T. Hofmann</i>	
TRYP SILIGASE ASSISTED BISPECIFIC ANTIBODY GENERATION .....	172
<i>J. Hohgardt</i>	
EVALUATION OF A COCKTAIL OF ANTI-RICIN ANTIBODIES FOR POST-EXPOSURE PROTECTION AGAINST RICIN INTOXICATION IN MICE .....	173
<i>W. Hu</i>	
DEVELOPMENT OF VEGFR-2 CHIMERIC ANTIGEN RECEPTOR (CAR) T CELLS FOR SOLID TUMOR THERAPY.....	174
<i>K. Huang</i>	
TCER - IN VITRO AND IN VIVO EFFICACY OF BISPECIFIC T CELL-ENGAGING RECEPTORS .....	175
<i>M. Hutt</i>	
DRUG DISCOVERY USING BISPECIFIC AND ASYMMETRIC ANTIBODY TECHNOLOGY.....	176
<i>T. Igawa</i>	
ADDRESSING LARGE-SCALE THERAPEUTIC VIRUS PRODUCTION USING HIGH QUALITY GRADE PEI-BASED TRANSFECTION REAGENTS.....	177
<i>J. Issenhuth</i>	
FIRST-IN-CLASS MEETS BEST-IN-CLASS: RAPID ANTIBODY DISCOVERY ON HARD TARGETS COMBINED WITH FINE-GRAINED ENGINEERING AND OPTIMIZATION.....	178
<i>S. Ives</i>	
IDENTIFICATION AND VALIDATION OF T CELL RECEPTORS AGAINST EDGE™- PREDICTED SHARED NEOANTIGENS FROM NEOANTIGEN/HLA-MATCHED PATIENT AND HEALTHY DONOR SAMPLES.....	179
<i>A. Jalloh</i>	
CB307: A NOVEL T-CELL COSTIMULATORY HUMABODY VH THERAPEUTIC FOR PSMA-POSITIVE TUMOURS.....	181
<i>C. Johnston</i>	
A NOVEL GENERALIZABLE SOLUTION FOR ENABLING BISPECIFIC ANTIBODIES TO CROSS THE BLOOD BRAIN BARRIER .....	182
<i>C. Jones</i>	
KINETIC APPROACH TO THE PROTEIN AGGREGATION MECHANISM DETERMINATION AND ITS IMPORTANCE FOR UNDERSTANDING OF POSSIBLE OUTCOMES OF THE AGGREGATION PROCESS .....	183
<i>D. Kara</i>	

ENGINEERING AN ANTI-HER2 BIPARATOPIC ANTIBODY WITH A MULTIMODAL MECHANISM OF ACTION .....	185
<i>F. Kast</i>	
DEVELOPMENT OF AN MS-BASED TOP-DOWN HIGH-THROUGHPUT APPROACH FOR CHARACTERIZATION OF NEW BIOLOGICAL ENTITIES AND BIOSIMILAR CANDIDATES .....	186
<i>J. Kast</i>	
EFFICIENT PRODUCTION OF NON-ANTIBODY SCAFFOLDS BY CORYNEX®.....	187
<i>Y. Kikuchi</i>	
NATIVE MS UNRAVELS A NON-COVALENTLY ASSOCIATED SIDE-PRODUCT IN THE HMW1 FRACTION OF 2+1 BISPECIFIC ANTIBODIES.....	188
<i>M. Koenig</i>	
A NOVEL DATA-INDEPENDENT-ACQUISITION (DIA) APPROACH TO DE NOVO ANTIBODY SEQUENCING.....	189
<i>J. Krieger</i>	
SIMPLIFY YOUR PURIFICATION: EXAMPLES FOR AUTOMATED TWO STEP PURIFICATION .....	190
<i>U. Krop</i>	
ONLINE IEX-MS CHARACTERIZATION AND MONITORING OF MAB CHARGE HETEROGENEITY USING AN OPTIMIZED CATION EXCHANGE RESIN AND COMPACT TOF MASS SPECTROMETER.....	191
<i>D. Lascoux</i>	
NOVEL INTESTINAL MICROBIOME-DERIVED PEPTIDES MODULATES IMMUNE CELL ACTIVITY AND THE TUMOR MICROENVIRONMENT .....	193
<i>S. Lau</i>	
DEVELOPMENT AND APPLICATIONS OF 10FN3-BASED MODULATORS OF ONCOGENIC TARGETS.....	194
<i>S. Lau</i>	
A CASE STUDY OF QUALITY BY DESIGN APPROACH TO VIRAL CLEARANCE IN DOWNSTREAM PROCESS DEVELOPMENT .....	195
<i>J. Lee</i>	
REGENERATIVE SPR SURFACES FOR SMALL MOLECULE KINETIC CHARACTERIZATION USING PROTEIN ADAPTORS .....	196
<i>W. Lee</i>	
HOST CELL RESIDUAL DNA TESTING IN REDUCED VOLUME QPCR REACTIONS USING ACOUSTIC LIQUID HANDLING .....	197
<i>A. Lejeune</i>	
MINIATURIZATION OF A FIVE PIECE PIK3CA PLASMID ASSEMBLY BY UTILIZING NEBUILDER® HIFI DNA ASSEMBLY CLONING KIT AND THE LABCYTE ECHO® 525 LIQUID HANDLER .....	198
<i>A. Lejeune</i>	
SPECIFIC ACTIVATION OF PRO-INFLIXIMAB ENHANCES SELECTIVITY AND SAFETY OF RHEUMATOID ARTHRITIS THERAPY .....	199
<i>W. Lin</i>	

IMPROVED PROTEIN RECOVERY WITH NEW GENERATION STREP-TACTIN XT SEPHAROSE CHROMATOGRAPHY COLUMNS.....	200
<i>E. Lind</i>	
STRATEGIES FOR HIGH-TITER PROTEIN EXPRESSION USING THE EXPICHO AND EXPI293 TRANSIENT EXPRESSION SYSTEMS .....	201
<i>C. Liu</i>	
CHARACTERIZATION OF ADENO-ASSOCIATED VIRUS (AAV) USING CAPILLARY ELECTROPHORESIS .....	202
<i>S. Lock</i>	
HIGH DENSITY (HD) EXPRESSION PLATFORM, THE ONE STOP SOLUTION FOR RECOMBINANT ANTIBODY PRODUCTION AT GENSCRIPT.....	203
<i>A. Luan</i>	
EFFICIENT DATA PROCESSING WORKFLOWS FOR IN-DEPTH, MS-BASED GLYCOANALYSIS OF BIOPHARMACEUTICALS.....	204
<i>J. McCarter</i>	
EFFICIENT SAMPLING OF THE B CELL REPERTOIRE TO FIND HIGH QUALITY ANTIBODIES.....	205
<i>R. McElhone</i>	
HALF-LIFE EXTENDED SOLUBLE ADAPTERS FOR EFFICIENT RE-TARGETING OF UNIVERSAL SWITCH ON/OFF CAR-T CELLS (UNICAR) AGAINST LEUKEMIA AND SOLID TUMORS.....	206
<i>J. Meyer</i>	
PROTEIN PRODUCTION, BIOCHEMICAL AND BIOPHYSICAL CHARACTERIZATION AS WELL AS X-RAY CRYSTALLOGRAPHY FOR BIOLOGICALS DURING EARLY DRUG DISCOVERY .....	208
<i>I. Montenbruck</i>	
END-TO-END WORKFLOW PLATFORM FOR INTEGRATED BIOPHARMACEUTICAL DEVELOPMENT .....	209
<i>M. Moravec</i>	
GENERATING POTENT AND SELECTIVE INHIBITORS OF KV1.3 ION CHANNELS BY FUSING VENOM DERIVED MINI PROTEINS INTO PERIPHERAL CDR LOOPS OF ANTIBODIES.....	210
<i>L. Moreels</i>	
HIGH-THROUGHPUT PEPTIDE-HLA COMPLEX GENERATION AND KINETIC SCREENINGS OF TCRS WITH PEPTIDE-RECEPTIVE HLA-A*02:01 MOLECULES .....	211
<i>A. Moritz</i>	
C-TAG AFFINITY TAG: FROM ROUTINE PROTEIN PURIFICATION TO USE IN A CGMP PRODUCTION PROCESS .....	212
<i>G. Morren</i>	
HIGH THROUGHPUT MICROSCALE ANTIBODIES PRODUCTION AND PURIFICATION TO ACCELERATE ANTIBODY DISCOVERY .....	213
<i>A. Muzi</i>	

RAPID THERAPEUTIC ANTIBODY DEVELOPMENT USING RENMAB™ MOUSE, A FULLY HUMAN ANTIBODY MOUSE .....	214
<i>G. Ng</i>	
EVALUATION OF INNOVATIVE ANTIBODY-FRAGMENT BASED TARGETED CONSTRUCTS AS TREATMENT OPTION FOR MEDULLOBLASTOMA .....	215
<i>J. Nielsen</i>	
GRAFTING SYNTHETIC AROMATIC COMPOUNDS IMPROVES THE POTENCY OF A PAN-NEUTRALIZING HIV ANTIBODY .....	217
<i>J. Nieva</i>	
COST ANALYSIS OF VEIN-TO-VEIN CAR T-CELL THERAPY: EFFECT OF AUTOMATED MANUFACTURING .....	218
<i>R. Noel</i>	
COMPLETE N- AND O- DEGLYCOSYLATION OF BIOPHARMACEUTICALS .....	219
<i>M. Nordgren</i>	
HIGHLY POTENT HEAVY CHAIN ONLY ANTIBODIES PROTECT MICE AGAINST MERS-COV INFECTION .....	220
<i>N. Okba</i>	
HUMANISED FAB AND SINGLE-CHAIN VARIABLE FRAGMENTS FOR MOLECULAR IMAGING OF ATHEROSCLEROSIS .....	221
<i>S. Pandey</i>	
ACCELERATING THE DISCOVERY OF THERAPEUTIC ANTIBODIES USING HIGH THROUGHPUT SPR .....	223
<i>J. Parisot</i>	
CC-1, A BISPECIFIC PSMA ANTIBODY IN AN OPTIMIZED FORMAT FOR TREATMENT OF PROSTATE CANCER AND SQUAMOUS CELL CARCINOMA OF THE LUNG .....	224
<i>M. Pfluegler</i>	
DEVELOPMENT AND CHARACTERISATION OF A LAG-3/PD-L1 BISPECIFIC AFFIMER® BIOTHERAPEUTIC .....	225
<i>V. Phatak</i>	
PROTEIN PRODUCTION IN PICHIA: A TOOLBOX FOR HIGH YIELD AND LOW O-GLYCOSYLATION .....	226
<i>N. Pirlot</i>	
HIGH-THROUGHPUT PLATFORM OF MONOCLONAL ANTIBODIES PURIFICATION .....	227
<i>T. Pizette</i>	
DIRECTED EVOLUTION OF AN ENHANCER FRAGMENT FOR THE IMPROVED SECRETION OF HETEROLOGOUS PROTEINS THROUGH HEMOLYSIN TYPE I SECRETION SYSTEM .....	228
<i>Z. Najafabadi</i>	
HIGH THROUGHPUT SINGLE B CELL SCREENING FROM IMMUNISED HUMAN ANTIBODY TRANSGENIC MICE .....	229
<i>R. Priest</i>	



FORMULATION CHALLENGES WITH A NEW CLASS OF TCR-BASED BISPECIFIC FUSION PROTEIN (IMMTAC®).....	230
<i>P. Ranglani</i>	
BEAT™ 2.0 - GLENMARK'S NEXT GENERATION BI- AND MULTISPECIFIC ANTIBODY PLATFORM.....	231
<i>C. Fecourt</i>	
DESIGNED MODULAR PROTEINS WITH TWO BINDING MOIETIES FOR INDUCED TARGET DEGRADATION .....	232
<i>J. Ripka</i>	
A BISPECIFIC ANTIBODY WITH ENHANCED BRAIN UPTAKE AND STRONG BINDING TO THE SOLUBLE PROTOFIBRILS OF AMYLOID BETA .....	233
<i>F. Rofo</i>	
COUPLING GENETIC VACCINATION AND NOVEL ANTIBODY SCREENING PLATFORMS: A FASTER AND EFFICIENT APPROACH IN MONOCLONAL ANTIBODY DISCOVERY FOR DIFFICULT TARGETS .....	234
<i>G. Roscilli</i>	
OVERCOMING LIMITATIONS OF CONVENTIONAL TAG SYSTEMS - STREP-TACTIN XT APPLICATIONS.....	235
<i>M. Rothe</i>	
GENEART™ STRINGS™ DNA LIBRARIES - THE FAST AND ECONOMIC WAY OF DNA LIBRARY PRODUCTION.....	236
<i>T. Santl</i>	
AUTOMATED COMPREHENSIVE CHARACTERIZATION AND QUANTIFICATION OF LOW-ABUNDANCE SEQUENCE VARIANTS IN A STANDARD MONOCLONAL ANTIBODY .....	237
<i>C. Schmid</i>	
ANTI-BIOTHERAPEUTIC ANTIBODY DEVELOPMENT AGAINST IPILIMUMAB WITH HUCAL PLATINUM.....	238
<i>L. Schmohl</i>	
AUTOMATED LOW PH DIGESTION AND COLUMN CONSIDERATIONS FOR PEPTIDE MAPPING OF BIOTHERAPEUTIC PROTEINS .....	239
<i>A. Schwahn</i>	
FROM RESEARCH TO DEVELOPMENT: OPTIMIZATION OF A T CELL ACTIVATION ASSAY FOR GMP USE .....	240
<i>A. Serchinger</i>	
IMMTAC®: ENGINEERING BISPECIFIC TCR-BASED FUSION PROTEINS, WITH HIGH SPECIFICITY AND AFFINITY, TO TREAT CANCER .....	241
<i>E. Sivertsson</i>	
SELECTING NOVEL AND DEVELOPABLE ANTIBODIES BY MAMMALIAN DISPLAY .....	242
<i>P. Slavny</i>	
SYNERGISTIC EFFECT OF GLYCO-ENGINEERING AND VLP-DISPLAY OF A VACCINE CANDIDATE EXPRESSED IN S2 CELLS .....	243
<i>M. Soegaard</i>	

NOVEL SYNTHETIC SHARK-HUMAN ANTIBODY LIBRARY TO COMBINE THE STABILITY OF VNARS WITH A HUMAN VL .....	244
<i>A. Zadeh</i>	
DESIGN OF A PORCINE IGG FORMAT WITH REDUCED IMMUNE EFFECTOR FUNCTIONS FOR AN INTRANASAL STUDY IN GÖTTINGEN MINIPIGS .....	245
<i>A. Zadeh</i>	
NOVEL HUMANIZED CTLA-4 FOR ASSESSMENT OF EFFICACY OF BIOLOGICS .....	246
<i>F. Sonego</i>	
DUTAFABS: BISPECIFIC THERAPEUTIC FAB FRAGMENTS WHICH CAN SIMULTANEOUSLY BIND TWO TARGETS WITH HIGH AFFINITY .....	247
<i>J. Speck</i>	
AFFIMER® ANTI-IDIOTYPIC BINDERS: HIGH-PERFORMING CRITICAL REAGENTS FOR DIVERSE CLINICAL NEEDS .....	248
<i>G. Spence</i>	
CONDITIONAL INTERNALIZATION OF PEGYLATED NANOMEDICINES BY PEG ENGAGERS FOR TRIPLE NEGATIVE BREAST CANCER THERAPY .....	249
<i>Y. Su</i>	
SUBUNIT MASS ANALYSIS AND MIDDLE-DOWN SEQUENCING IN THE ASSESSMENTS OF PROTEIN CLIPPING VARIANTS .....	250
<i>D. Suckau</i>	
TARGETED THERAPY FOR GASTRIC CANCER .....	252
<i>W. Sun</i>	
CHARACTERISATION OF BI-SPECIFIC T-CELL ENGAGER (BITE) ANTIBODY-MEDIATED IMMUNE CELL KILLING USING A COMBINED LIVE-CELL ANALYSIS AND FLOW CYTOMETRY WORKFLOW .....	253
<i>C. Szybut</i>	
MULTIVARIATE OPTIMIZATION AND QUALIFICATION OF A RP-CAD METHOD FOR SIMULTANEOUS MEASUREMENT OF MULTIPLE PROCESS RESIDUES .....	255
<i>R. Tagore</i>	
SENSITIVE CIRCULAR DICHROISM ANALYSIS OF THERAPEUTIC ANTIBODIES .....	256
<i>M. Textor</i>	
OVERCOMING THE DIFFICULTIES IN OBTAINING PURE RECOMBINANT PROTEIN .....	257
<i>S. Thieffine</i>	
EXPISF™ EXPRESSION SYSTEM: A CHEMICALLY DEFINED BACULOVIRUS-BASED EXPRESSION SYSTEM FOR ENHANCED PROTEIN AND VIRUS PRODUCTION IN SF9 CELLS .....	258
<i>K. Thompson</i>	
AN INTEGRATED AND STRAIGHTFORWARD LC-MS-BASED WORKFLOW FOR HCPS ACCURATE QUANTITY ASSESSMENT: APPLICATION TO BIOPROCESS CHARACTERIZATION .....	259
<i>M. Trauchessec</i>	

REDUCE RISK OF FAILURE IN VIRUS CLEARANCE STUDIES USING ROBUST SCALE-DOWN CHROMATOGRAPHY TOOLS.....	260
<i>L. Troeng</i>	
TCER - ENGINEERING AND ARMING OF SOLUBLE T CELL RECEPTORS FOR TARGETING OF TUMOR SPECIFIC HLA LIGANDS .....	261
<i>F. Unverdorben</i>	
GAMMA DELTA TCR ANTI-CD3 BISPECIFIC MOLECULES (GABS) AS NOVEL IMMUNOTHERAPEUTIC COMPOUNDS .....	262
<i>E. Diest</i>	
RGD BICYCLES: HIGH-AFFINITY LIGANDS FOR SELECTIVE INTEGRIN-TARGETING IN CANCER THERAPY .....	263
<i>J. Heteren</i>	
REAL SAMPLES, REAL DATA: MOLECULAR INTERACTION ANALYSIS BY GRATING-COUPLED INTERFEROMETRY .....	264
<i>M. Vegh</i>	
ACCELERATING ANTIBODY DRUG DEVELOPMENT WITH SUBDOMAIN-SPECIFIC AFFINITY LIGANDS .....	265
<i>M. Vis</i>	
INNOVATIVE ANALYTICAL TECHNIQUES FOR BIOPROCESS INVESTIGATION .....	266
<i>N. Vollmer</i>	
ISOLATION AND CHARACTERIZATION OF LIGHT CHAIN MISASSEMBLED BISPECIFIC ANTIBODY VARIANTS BY HYDROPHOBIC INTERACTION CHROMATOGRAPHY AND KNOWLEDGE USE FOR PRODUCTION CELL LINE OPTIMIZATION .....	267
<i>T. Hirschheydt</i>	
A HYDROPHOBIC ANION EXCHANGE RESIN FOR REFINED SELECTIVITY AND RECOVERY .....	268
<i>C. Voss</i>	
ROBUST ANTI-TUMOR ACTIVITY AND DOWNREGULATION OF EGFR SIGNALING AND PD-L1 EXPRESSION BY AEGFR PAR T-CELLS .....	269
<i>C. Wagner</i>	
TCER PLATFORM - SELECTION AND VALIDATION OF EFFECTIVE AND SAFE BISPECIFIC T CELL-ENGAGING RECEPTOR (TCER) MOLECULES FOR CANCER IMMUNOTHERAPY.....	271
<i>C. Wagner</i>	
PRE-ART: PREDICTIVE REAGENT ANTIBODY REPLACEMENT TECHNOLOGY .....	272
<i>B. Wagstaffe</i>	
ECHO™ BASAL AND FEED MEDIUM FOR THE CHO CELLS: EASY, ECONOMICAL, CHEMICALLY DEFINED ANIMAL ORIGIN-FREE, SIMPLE ONE PART FORMULATION MEDIUM FOR THE PRODUCTION OF MONOCLONAL ANTIBODIES .....	273
<i>N. Wellens</i>	
CONSISTENT, LONG-TERM PD1 BLOCKADE USING A SYNGENEIC, ENGINEERED ANTI-PD1 ANTIBODY: SUPERIOR TOOLS FOR CONSISTENT AND MORE MEANINGFUL IMMUNOTHERAPY RESEARCH.....	274
<i>I. Wilkinson</i>	

PROMETHEUS™: A NOVEL APPROACH FOR ENGINEERING MANUFACTURABLE HUMANIZED ANTIBODIES .....	275
<i>I. Wilkinson</i>	
FULLY MURINE KNOB-INTO-HOLE BISPECIFIC AS SURROGATE MOLECULE FOR DRUG DEVELOPMENT MODELS .....	276
<i>I. Wilkinson</i>	
RAPID ASSEMBLY OF SYNTHETIC DNA LIBRARIES FOR PROTEIN ENGINEERING AND GENERATING ANTIBODY DIVERSITY .....	277
<i>L. Wolf</i>	
SHAKE IT UP - HOW EFFICIENT EVALUATION OF MEDIA, SHEAR PROTECTION AND RAW MATERIALS CAN ENHANCE TRANSFECTION .....	278
<i>A. Wuest</i>	
DISCOVERY OF NKP46 ANTIBODY FOR BISPECIFIC ANTIBODY DEVELOPMENT USING COMMON LIGHT CHAIN APPROACH .....	279
<i>T. Yang</i>	
DISCOVERY OF POTENT AND SPECIFIC MMP-9 INHIBITORS BINDING TO ONLY ACTIVE FORM FROM DAIICHI-SANKYO ORIGINAL ENGINEERED SPINK2 LIBRARY .....	280
<i>H. Yano</i>	
A NOVEL COMMERCIAL UTILITY OF IPS CELLS: FULLY HUMAN BIOLOGIC MANUFACTURING .....	281
<i>Y. Zahid</i>	
FDA PLATE AND NANODSF - A READY TO USE, ALL-IN-ONE SOLUTION FOR ANTIBODY STABILITY TESTING AND PRE-FORMULATION .....	283
<i>B. Zimmer</i>	
OPTIMIZED EXPRESSION OF MEMBRANE PROTEINS IN THE EXP1293 AND EXPICHO EXPRESSION SYSTEMS: NEW TOOLS FOR DIFFICULT TO EXPRESS PROTEINS .....	284
<i>J. Zmuda</i>	
IN VIVO PHAGE DISPLAY SELECTION FOR DEVELOPMENT OF HIGHLY SPECIFIC ANTIBODY DRUG CONJUGATES FOR NON-HODGKIN'S LYMPHOMA .....	285
<i>A. Andre</i>	
ALGORITHM-BASED FORMULATION DEVELOPMENT INCLUDING A DOE CONCEPT ENHANCES FORMULATION DEVELOPMENT FOR THERAPEUTIC ANTIBODIES AND VIRUSES .....	287
<i>J. Gerstenberger</i>	
HIGHLY SENSITIVE PROTEIN AGGREGATION AND THERMAL STABILITY ASSAY IN A HIGH THROUGHPUT FORMAT .....	288
<i>H. Harma</i>	
DEVELOPMENT OF CCAP METHOD TO MODIFY ANTIBODY SITE-SPECIFICALLY .....	289
<i>Y. Ito</i>	
OVERCOMING THE BLOOD-BRAIN BARRIER: IN VIVO PHAGE DISPLAY SELECTION OF SINGLE-DOMAIN ANTIBODIES FOR DRUG DELIVERY INTO THE BRAIN .....	290
<i>M. Silva</i>	

**Author Index**